Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping adrenal tumors could lower blood pressure without surgery

NCT ID NCT02756754

Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a procedure called radiofrequency ablation, which uses heat to destroy a small adrenal gland tumor that causes high blood pressure. Researchers wanted to see if it could safely lower blood pressure in 31 patients with primary aldosteronism. The goal was to reduce or stop the need for blood pressure medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiofrequency ablation
What this could lead to
If successful, this could provide a less invasive treatment option for patients with primary aldosteronism, potentially reducing or eliminating the need for lifelong blood pressure medication.
What could go wrong
This is a small, early-phase study with only 31 participants, so results may not apply to everyone. The procedure carries risks such as bleeding or damage to nearby tissues, and long-term effectiveness is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

31 people

The number who actually took part.

Started

Nov 2016

Finished

May 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * hypertension confirmed with ambulatory blood pressure monitoring * primary aldosteronism demonstrated by hormonal assays: active renin (pg/ml) or plasma renin activity (ng/ml/h) and plasma aldosterone measured twice at baseline after an overnight fast, in sitting or recumbent position * selective adrenal venous sampling after 40 years of age * unilateral adrenal nod on CT scan \<4cm * adrenal radiofrequency ablation procedure of judged technically possible by radiologists Exclusion Criteria: * bilateral adrenal nods * primary aldosteronism due to bilateral adrenal hyperplasia or macronodular hyperplasia * lack of documented primary aldosteronism * maximum tumor diameter greater than 4 cm * Cushing syndrome or Pheochromocytoma * when adrenal venous sampling is refused by the patient * coagulopathy * pregnant women * patient with potentially inaccessible nodule

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenal adenoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenal cortex adenoma aldosterone-producing adrenal cortex adenoma ectopic ACTH secretion syndrome hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adrenal adenoma Primary aldosteronism

Contacts and locations

Locations

  • CHU Bordeaux

    Bordeaux, France

  • CHU de Toulouse

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.